NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Lipids, Inflammation, and CV Risk in RA

CompletedN/A

Sponsor: Brigham and Women's Hospital

Conditions: Rheumatoid Arthritis, Cardiovascular Disease

Interventions: Certolizumab

Countries: United States

The objective of this study was to examine the relationship between inflammation, lipids, and cardiovascular risk in rheumatoid arthritis. The central hypothesis is that reducing inflammation will reduce cardiovascular risk as measured by coronary flow reserve. Additionally, we hypothesized that lipid levels may have a weaker correlation with CV risk compared to the general population.

Eligibility overview

Sex: ALL

Age: 35 Years to 90 Years

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* RA diagnosed by a rheumatologist
* Fulfills the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) Criteria for RA
* Age\>35
* Active RA as defined by treating rheumatologist
* Biologic DMARD naive

Exclusion Criteria:

* Patients on statin or PCSK9 inhibitor therapy
* Corticosteroid therapy \>10mg prednisone or its equivalent as a maintenance treatment
* Pregnancy
* Unstable angina (chest pain) or shortness of breath
* Severe valvular heart disease
* Myocarditis
* Pericarditis
* Asthma with active wheezing
* History of lymphoproliferative disease or melanoma (stage two or higher), active malignancy, or cancer treatment in the last 5 years
* Active infectious disease (HIV, Tuberculosis, or Hepatitis B/C)

Locations (1)

Boston, Massachusetts, United States